LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article: Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries.

Chow, Clara Kayei / Nguyen, Tu Ngoc / Marschner, Simone / Diaz, Rafael / Rahman, Omar / Avezum, Alvaro / Lear, Scott A / Teo, Koon / Yeates, Karen E / Lanas, Fernando / Li, Wei / Hu, Bo / Lopez-Jaramillo, Patricio / Gupta, Rajeev / Kumar, Rajesh / Mony, Prem K / Bahonar, Ahmad / Yusoff, Khalid / Khatib, Rasha /
Kazmi, Khawar / Dans, Antonio L / Zatonska, Katarzyna / Alhabib, Khalid F / Kruger, Iolanthe Marike / Rosengren, Annika / Gulec, Sadi / Yusufali, Afzalhussein / Chifamba, Jephat / Rangarajan, Sumathy / McKee, Martin / Yusuf, Salim

BMJ global health

2020  Volume 5, Issue 11

Abstract: ... income countries (HICs), upper and lower middle-income countries (UMICs, LMICs) and low-income countries ... economic factors.: Results: Of 163 466 participants, there were 93 200 with high CVD risk from 21 countries ... Conclusion: Lower availability and affordability of essential CVD medicines were associated with higher risk ...

Abstract Objectives: We aimed to examine the relationship between access to medicine for cardiovascular disease (CVD) and major adverse cardiovascular events (MACEs) among people at high risk of CVD in high-income countries (HICs), upper and lower middle-income countries (UMICs, LMICs) and low-income countries (LICs) participating in the Prospective Urban Rural Epidemiology (PURE) study.
Methods: We defined high CVD risk as the presence of any of the following: hypertension, coronary artery disease, stroke, smoker, diabetes or age >55 years. Availability and affordability of blood pressure lowering drugs, antiplatelets and statins were obtained from pharmacies. Participants were categorised: group 1-all three drug types were available and affordable, group 2-all three drugs were available but not affordable and group 3-all three drugs were not available. We used multivariable Cox proportional hazard models with nested clustering at country and community levels, adjusting for comorbidities, sociodemographic and economic factors.
Results: Of 163 466 participants, there were 93 200 with high CVD risk from 21 countries (mean age 54.7, 49% female). Of these, 44.9% were from group 1, 29.4% from group 2 and 25.7% from group 3. Compared with participants from group 1, the risk of MACEs was higher among participants in group 2 (HR 1.19, 95% CI 1.07 to 1.31), and among participants from group 3 (HR 1.25, 95% CI 1.08 to 1.50).
Conclusion: Lower availability and affordability of essential CVD medicines were associated with higher risk of MACEs and mortality. Improving access to CVD medicines should be a key part of the strategy to lower CVD globally.
MeSH term(s) Costs and Cost Analysis ; Developing Countries ; Female ; Humans ; Income ; Male ; Middle Aged ; Poverty ; Prospective Studies
Keywords covid19
Language English
Publishing date 2020-11-04
Publishing country England
Document type Journal Article ; Research Support, Non-U.S. Gov't
ISSN 2059-7908
ISSN 2059-7908
DOI 10.1136/bmjgh-2020-002640
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top